TVM Capital Life Science operates with an integrated team from its offices in Montreal and Munich. Our mission is to invest in the development of exciting life science products and the growth of substantial companies in the field that are or aspire to be innovative leaders in their market segment. We are resourceful and supportive strategic partners to founders, owners, managers and co-investors alike.
Since 1984, TVM Capital has made almost 120 investments in life science companies in Europe and the United States. Among others, TVM Capital was the Series A lead investor in the following publicly listed companies with market capitalizations that at some point were or still are greater than of €1 billion: Qiagen, Sequenom, Actelion and Intercell. TVM Capital also led the Series A investments in Direvo and Jerini, the largest M&A transactions in the history of German biotechnology. We are proud to have been investors in companies such as Morphosys, Evotec and Pharmasset, ‘household names’ for drug discovery in the pharmaceutical industry today.
The TVM Capital Life Science Practice currently manages in excess of €900 million from more than 50 investors. Our investment professionals draw upon the experience, international approach and demonstrated success of about 80 exits from the LS portfolio. These exits include nearly 40 initial public offerings on the NASDAQ, and the London, Frankfurt, Zurich and Vienna Stock Exchanges and 25 trade sales and mergers. The investment team of TVM Life Science combines long-standing international investment and company building experience with their track record of dedicated board work, extensive global networks in the world of life science research and product development and a direct knowledge of the local markets we invest in.
With more than two decades of experience in picking promising entrepreneurs, concepts and products for development, and building successful entrepreneurial companies, we are acutely aware of what it takes to build a world class technology, product or company, and astute at supporting management teams to bring companies and projects to value inflection points. We have shown dozens of times that we are able to finance a company through the more capital intensive stages of development, from our own investment funds as well as a strong syndication capability. This is what it takes to enable companies to fully realize their potential.
In recent years we have conceptually paved the way for an innovative life science venture capital investment strategy. This novel approach to creating financial success as well as excellent products is designed to be more capital efficient through focusing the capital on where the true value in a project usually lies: in the proof-of-concept data in man. After implementing this strategy throughout the last four years in various TVM Capital portfolio companies, we firmly believe this strategy is very well suited to provide our investors with competitive returns from investing in life science innovation going forward.